| Homo Zin Cada | First Name: | | | |
|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|------------------------|---------------------------|
| | Date of birth: | | T _ | 1_ |
| COVID-19 vaccination screening questions: | 1. Is your child sick today? (minor illness is not a con | traindication to vaccination) | ☐ Yes | □ No |
| | 2. Does your child have a life-threatening allergy to a vaccines? If yes, DO NOT VACCINATE. Check with y | | □ Yes | □No |
| | 3. I understand that the COVID-19 vaccination is a m children less than 5 years old, and I agree that my doses at the time required. | | □ Yes | □No |
| | 4. If my child is 5-11 years old, and has been previous has been at least 2 months since the last previous | | □ Yes | □No |
| | See reverse for vaccination recommendations | | | |
| INFORMED CON | ISENT: | | 1 | |
| I, (print name): vaccination. | , he | reby acknowledge and assume | e the risk | of COVID- |
| | COVID-19 Vaccination is not an FDA-approved med gency Use Authorization (EUA) to permit its use for A for this vaccine. | , | • | |
| vaccine may be ef known and poten risks of the drug's | EUA criteria and the scientific evidence available, it ffective in the prevention of COVID-19, and that, git tial benefits to treat this serious or life-threatening use. there is limited information known about the safet | ven there are no available alte ; virus currently outweigh the l | rnative va known an | accines, th d potentia |
| | pected side effects may occur. Known possible side | | VID 15 Va | conic. |
| face, or the Immune see Pain/swel | eactions: low blood pressure, changes in heartbeat, nroat, rash, nausea, vomiting, sweating, or shivering system reaction: fever, muscle/joint aching, myalgion lling/redness at injection site ly: inflammation of the heart muscle or the tissues | g, possible during or after infu a, headache, fatigue, nausea/v | sion | g of the li _l |
| | COVID-19 vaccine may cause additional risks, some risks described above, as well as those risks for the | • | known a | t this tim |
| vaccine is given sheet when avai | o have the COVID-19 vaccine given to my child. I u under Emergency Use Authorization for persons 6 lable before my child receives the vaccine. I under earing a mask when recommended and will contin | mo-11 years old and I will revestand that receiving the vacci | riew the i | nformatio ot preclu |
| Patient Re | epresentative Signature & Relationship to patient | Date | | |
| | info given:/ | Date of vaccine info sheet: 9/2023 | | |
| Lot #: | Mfg: | CPT Code: | | |
| | Pfizer Biontech 2023-2024 PEDIATRIC COVID-19 VACCINE6mo-4yo (YELLOW) | | | |
| | Fire 14ths (DILLE) | | | |
| | 5yo-11yo (BLUE) | | | |

_**0.3ml** ıм

PEDIATRIC Pfizer

Deltoid R____ L___ Vastus Lateralis R____ L_



Individuals 6 Months Through 4 Years of Age by Pfizer-BioNTech COVID-19 Vaccination Status

| | Pfizer-BioNTech COVID-19 | |
|-------------------------|-----------------------------|------------------------------------|
| Number of | Vaccine, | |
| Previous Doses | (2023-2024 | Pfizer-BioNTech COVID-19 |
| of | Formula) | Vaccine (2023-2024 |
| Pfizer-BioNTech | Vial Cap and | Formula) |
| COVID-19 | Label Border | Dosing Regimen, Dose and |
| vaccine(s) ^a | Color | Schedule ^b |
| | | 3 doses ^d , 0.3 mL each |
| | | Dose 1: Week 0 |
| 0 ° | Yellow | Dose 2: Week 3 |
| | | Dose 3: ≥8 weeks after |
| | | Dose 2 |
| | | 2 doses ^d , 0.3 mL each |
| | | Dose 1: 3 weeks after |
| | | receipt of the previous |
| 1 | Yellow | dose of Pfizer-BioNTech |
| | | COVID-19 vaccine ^a |
| | | Dose 2: ≥8 weeks after |
| | | Dose 1 |
| | | Single dose, 0.3 mL |
| 0.4-4 | Mallann | ≥8 weeks after receipt of |
| 2 to 4 | Yellow | the last previous dose of |
| | | Pfizer-BioNTech |
| | | COVID-19 vaccine ^a |

- Previous doses of Pfizer-BioNTech COVID-19 vaccine(s) refers to doses with Pfizer-BioNTech COVID-19 Vaccine (Original monovalent) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5). These vaccines are no longer authorized for use in the United States.
- For individuals with certain kinds of immunocompromise previously vaccinated with Pfizer-BioNTech COVID-19 vaccines, see text below tables for dosing information.
- Not previously vaccinated with any COVID-19 vaccine.
- For individuals turning from 4 to 5 years of age during the vaccination series. administer all doses with Pfizer-BioNTech COVID-19 Vaccine (2023-2024) Formula) supplied in vials with yellow caps and labels with yellow borders.

Individuals 5 Years Through 11 years of Age Irrespective of COVID-19 Vaccination Status

| Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) Vial Cap and Label Border | Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) Dosing Regimen, Dose and | | |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Color | Schedule ^a | | |
| Blue | Single dose, 0.3 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine ^b | | |